If you are a UMMC patient interested in oral antivirals, please consult your UMMC provider for a referral.
To qualify for treatment, UMMC patients must:
About Oral Antivirals
The FDA has authorized PAXLOVID and MOLNUPIRAVIR for some adults and children with mild to moderate COVID-19. When started early in the disease, treatment with these agents may help keep people from getting worse. The treatment is not approved for cases that have advanced past the mild to moderate stage, so it’s important to begin treatment as soon as possible.
Note: Paxlovid and Molnupiravir should not be used for patients who are hospitalized with COVID-19, require oxygen therapy for COVID-19, or have an increase in baseline oxygen flow rate due to COVID-19.